Prospective Grant of Co-Exclusive License: Device and System for Expression Microdissection (xMD), 16347 [2014-06413]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 57 / Tuesday, March 25, 2014 / Notices
micro-dissection of biological specimens, as
covered by the Licensed Patent Right.
Excluded from the exclusive field of use are
(1) methods, kits, and related consumables
that are used independent of the devices or
systems by individual researchers employed
at non-profit and academic institutions, if
such kits were built by the researchers
themselves from component parts and used
for their own individual research purposes,
and (2) diagnostic services performed using
devices, systems, kits and related
consumables purchased from Ventana or
Ventana’s authorized distributor(s) by those
persons employed at non-profit and
academic institutions that purchased the
devices, systems, kits and related
consumables used in the diagnostic services,
shall not infringe Ventana’s rights.
Dated: March 11, 2014.
Michael Lauer,
Director, DCVS, NHLBI, NIH.
Dated: March 11, 2014.
Lynn Susulske,
NHLBI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. 2014–06401 Filed 3–24–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive
License: Device and System for
Expression Microdissection (xMD)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR Part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
co-exclusive commercial license
agreement to practice the inventions
embodied in International PCT
Application S/N PCT/US03/23317 (HHS
Ref. No. E–113–2003/0–PCT–02) filed
July 23, 2003, which published as WO
2004/068104 on August 12, 2004, now
expired; U.S. Patent No. 7,709,047 (HHS
Ref. No. E–113–2003/0–US–03) issued
May 4, 2010; U.S. Patent Application S/
N 12/753,566 (HHS Ref. No. E–113–
2003/0–US–07) filed April 2, 2010; U.S.
Patent No. 7,695,752 (HHS Ref. No. E–
113–2003/1–US–01) issued April 13,
2010; U.S. Patent No. 8,460,744 (HHS
Ref. No. E–113–2003/1–US–02) issued
June 11, 2013; Australian Patent No.
2003256803 (HHS Ref. No. E–113–2003/
0–AU–04) issued January 21, 2010;
Australian Patent No. 2009250964 (HHS
Ref. No. E–113–2003/0–AU–06) issued
March 25, 2013; and Canadian Patent
No. 2513646 (HHS Ref. No. E–113–
2003/0–CA–05) issued September 17,
2013, all entitled; ‘‘Target Activated
Microtransfer’’; and all continuing
applications and foreign counterparts to
Ventana Medical Systems, Inc. a
company having a place of business in
Arizona. The patent rights in these
inventions have been assigned to the
Government of the United States of
America.
The prospective co-exclusive license
territory may be ‘‘worldwide,’’ and the
field of use may be limited to the
following:
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
Devices, systems, kits and related
consumables, and methods using device,
systems, kits and related consumables, for
VerDate Mar<15>2010
18:16 Mar 24, 2014
Jkt 232001
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before April
9, 2014 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated co-exclusive license
should be directed to: Kevin W. Chang,
Ph.D., Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–5018; Facsimile: (301) 402–
0220; Email: changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
subject technologies are methods,
devices, and kits for target activated
transfer of a target from a biological
sample such as a tissue section,
comprising: Contacting the biological
sample with a reagent that selectively
acts on the target within the biological
sample; placing a transfer surface
adjacent the biological sample, wherein
the reagent produces a change in the
transfer surface by heating the target;
heating the target to produce a change
in the transfer surface and selectively
adhere the target to the transfer surface,
or to selectively increase permeability of
the transfer surface to the target; and
selectively removing the target from the
biological sample by removing the
transfer surface and the adhered target
from the biological sample, or by
moving the target through the transfer
surface.
The prospective co-exclusive
commercial license will be royalty
bearing and will comply with the terms
and conditions of 35 U.S.C. 209 and 37
CFR Part 404. The prospective coexclusive commercial license may be
granted unless within fifteen (15) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
DATES:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
16347
with the requirements of 35 U.S.C. 209
and 37 CFR Part 404.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated co-exclusive
license. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 19, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–06413 Filed 3–24–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of T Cell
Receptors for Adoptive Transfer in
Humans to Treat Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR 404, that
the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to Kite
Pharma, Inc., which is located in Los
Angeles, California to practice the
inventions embodied in the following
patent applications:
1. U.S. Provisional Patent Application
No. 61/650,020 filed May 22, 2012
entitled ‘‘Murine anti-NY–ESO–1 T
cell receptors’’ (HHS Ref No. E–
105–2012/0–US–01) and
2. PCT Application No. PCT/US13/
042162 filed May 22, 2013 entitled
‘‘Murine anti-NY–ESO–1 T cell
receptors’’ (HHS Ref No. E–105–
2012/0–PCT–02)
The patent rights in these inventions
have been assigned to the United States
of America. The prospective exclusive
license territory may be worldwide and
the field of use may be limited to the
development, manufacture, distribution,
sale, and use of the compositions and
methods set forth in the Licensed Patent
Rights using genetically engineered
autologous T lymphocytes derived from
the peripheral blood of humans for the
treatment of NY–ESO–1-expressing
cancers.
SUMMARY:
E:\FR\FM\25MRN1.SGM
25MRN1
]]>Agencies
[Federal Register Volume 79, Number 57 (Tuesday, March 25, 2014)]
[Notices]
[Page 16347]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-06413]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive License: Device and System for
Expression Microdissection (xMD)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
Part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of a co-exclusive
commercial license agreement to practice the inventions embodied in
International PCT Application S/N PCT/US03/23317 (HHS Ref. No. E-113-
2003/0-PCT-02) filed July 23, 2003, which published as WO 2004/068104
on August 12, 2004, now expired; U.S. Patent No. 7,709,047 (HHS Ref.
No. E-113-2003/0-US-03) issued May 4, 2010; U.S. Patent Application S/N
12/753,566 (HHS Ref. No. E-113-2003/0-US-07) filed April 2, 2010; U.S.
Patent No. 7,695,752 (HHS Ref. No. E-113-2003/1-US-01) issued April 13,
2010; U.S. Patent No. 8,460,744 (HHS Ref. No. E-113-2003/1-US-02)
issued June 11, 2013; Australian Patent No. 2003256803 (HHS Ref. No. E-
113-2003/0-AU-04) issued January 21, 2010; Australian Patent No.
2009250964 (HHS Ref. No. E-113-2003/0-AU-06) issued March 25, 2013; and
Canadian Patent No. 2513646 (HHS Ref. No. E-113-2003/0-CA-05) issued
September 17, 2013, all entitled; ``Target Activated Microtransfer'';
and all continuing applications and foreign counterparts to Ventana
Medical Systems, Inc. a company having a place of business in Arizona.
The patent rights in these inventions have been assigned to the
Government of the United States of America.
The prospective co-exclusive license territory may be
``worldwide,'' and the field of use may be limited to the following:
Devices, systems, kits and related consumables, and methods
using device, systems, kits and related consumables, for micro-
dissection of biological specimens, as covered by the Licensed
Patent Right. Excluded from the exclusive field of use are (1)
methods, kits, and related consumables that are used independent of
the devices or systems by individual researchers employed at non-
profit and academic institutions, if such kits were built by the
researchers themselves from component parts and used for their own
individual research purposes, and (2) diagnostic services performed
using devices, systems, kits and related consumables purchased from
Ventana or Ventana's authorized distributor(s) by those persons
employed at non-profit and academic institutions that purchased the
devices, systems, kits and related consumables used in the
diagnostic services, shall not infringe Ventana's rights.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
April 9, 2014 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated co-exclusive
license should be directed to: Kevin W. Chang, Ph.D., Senior Licensing
and Patenting Manager, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; Telephone: (301) 435-5018; Facsimile: (301) 402-0220;
Email: changke@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The subject technologies are methods,
devices, and kits for target activated transfer of a target from a
biological sample such as a tissue section, comprising: Contacting the
biological sample with a reagent that selectively acts on the target
within the biological sample; placing a transfer surface adjacent the
biological sample, wherein the reagent produces a change in the
transfer surface by heating the target; heating the target to produce a
change in the transfer surface and selectively adhere the target to the
transfer surface, or to selectively increase permeability of the
transfer surface to the target; and selectively removing the target
from the biological sample by removing the transfer surface and the
adhered target from the biological sample, or by moving the target
through the transfer surface.
The prospective co-exclusive commercial license will be royalty
bearing and will comply with the terms and conditions of 35 U.S.C. 209
and 37 CFR Part 404. The prospective co-exclusive commercial license
may be granted unless within fifteen (15) days from the date of this
published notice, the NIH receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR Part 404.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated co-exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 19, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-06413 Filed 3-24-14; 8:45 am]
BILLING CODE 4140-01-P
